Katharine Clapham

Cardiologist, pulmonary hypertension specialist at University of Utah

[Katharine Clapham @ktroseclapham]

Thank you to @pnatarajanmd for an inspiring and informative ground rounds presentation on polygenic risk scores for CAD! @StavrosDrakos @KevinShahMD

[phaware® @phaware]

Katharine Clapham, MD from @UofUHealth discusses methamphetamine-associated pulmonary arterial hypertension which is a type of PH the medical community has grown increasingly aware of, which there are some new emerging treatments. phaware® podcast ep 416 https://t.co/49Ll6FQYm7

[Katharine Clapham @ktroseclapham]

Congratulations Jennalynn Mayeux on an excellent presentation helping us to understand the new guidelines at the 19th Annual Update in Pulmonary Hypertension!

[Pradeep Natarajan @pnatarajanmd]

Diagnosed chronic thromboembolic pulmonary hypertension (CETPH) is very rare.
However, using a VTE polygenic risk score, we observe that a larger fraction of pulmonary hypertension likely falls on a CETPH spectrum https://t.co/3aYbGW7dLz @Circ_Gen by @ktroseclapham

[Katharine Clapham @ktroseclapham]

Happy to share work from our Utah Program highlighting geographic variation in causes of PAH
https://t.co/7SMogKHmxe

[Katharine Clapham @ktroseclapham]

Congratulations Alexa Miller ⁦@ArtsPractica⁩ on a great talk on uncertainty in medicine at dotMD! https://t.co/n9WbDg791q